Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Benzenamine, 4-[2-(5-ethyl-2-pyridinyl)ethoxy]-, also known as Vericiguat, is a chemical compound with potential therapeutic applications. It is a soluble guanylate cyclase stimulator that has shown promise in the treatment of certain cardiovascular diseases, particularly heart failure. By activating soluble guanylate cyclase, Vericiguat can increase cyclic guanosine monophosphate (cGMP) levels in the body, leading to vasodilation and improved cardiac function.

85583-40-0 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 85583-40-0 Structure
  • Basic information

    1. Product Name: Benzenamine, 4-[2-(5-ethyl-2-pyridinyl)ethoxy]-
    2. Synonyms:
    3. CAS NO:85583-40-0
    4. Molecular Formula: C15H18N2O
    5. Molecular Weight: 242.321
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 85583-40-0.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: Benzenamine, 4-[2-(5-ethyl-2-pyridinyl)ethoxy]-(CAS DataBase Reference)
    10. NIST Chemistry Reference: Benzenamine, 4-[2-(5-ethyl-2-pyridinyl)ethoxy]-(85583-40-0)
    11. EPA Substance Registry System: Benzenamine, 4-[2-(5-ethyl-2-pyridinyl)ethoxy]-(85583-40-0)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 85583-40-0(Hazardous Substances Data)

85583-40-0 Usage

Uses

Used in Pharmaceutical Industry:
Benzenamine, 4-[2-(5-ethyl-2-pyridinyl)ethoxy]is used as a cardiovascular therapeutic agent for the treatment of chronic heart failure. It is employed to reduce the risk of cardiovascular death and heart failure hospitalization in patients with this condition.
Used in Cardiovascular Applications:
Benzenamine, 4-[2-(5-ethyl-2-pyridinyl)ethoxy]is used as a soluble guanylate cyclase stimulator for increasing cGMP levels in the body, leading to vasodilation and improved cardiac function. This makes it a promising candidate for the development of novel cardiovascular therapies.
Used in Pulmonary Hypertension Treatment:
Benzenamine, 4-[2-(5-ethyl-2-pyridinyl)ethoxy]has shown potential for the treatment of pulmonary hypertension, where it may help in managing the symptoms and improving the quality of life for patients suffering from this condition.
Used in Kidney Disease Management:
Benzenamine, 4-[2-(5-ethyl-2-pyridinyl)ethoxy]has demonstrated potential in the treatment of kidney disease, where it may contribute to the management of the condition and potentially slow down its progression.

Check Digit Verification of cas no

The CAS Registry Mumber 85583-40-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,5,5,8 and 3 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 85583-40:
(7*8)+(6*5)+(5*5)+(4*8)+(3*3)+(2*4)+(1*0)=160
160 % 10 = 0
So 85583-40-0 is a valid CAS Registry Number.

85583-40-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-[2-(5-ethylpyridin-2-yl)ethoxy]aniline

1.2 Other means of identification

Product number -
Other names 4-[2-(5-ethyl-2-pyridyI)ethoxy]aniline

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:85583-40-0 SDS

85583-40-0Relevant articles and documents

Preparation method of piogelimide

-

Paragraph 0024; 0028; 0031; 0034, (2020/11/26)

The invention provides a preparation method of piogelimide, which comprises the following steps: by using 4-[2- (5-ethyl-2-pyridyl)ethyoxyl]nitrobenzene as a starting material, methanol as a solvent and Raney Ni as a catalyst, carrying out catalytic hydrogenation, carrying out pressure filtration on the reaction solution into hydrobromic acid to carry out acidification reaction, and adding cuprousoxide, methyl acrylate and acetone into the system; dropwise adding a sodium nitrite solution, drying the organic solvent by distillation under reduced pressure after the reaction is finished, addingammonia water, alkalifying the solution by using liquid caustic soda, and extracting the product by using ethyl acetate; and adding thiourea and sodium acetate into the ethyl acetate solution, performing heating reflux until the reaction is finished, cooling the reaction product, adding water, spin-drying the reaction product, and refining the product by using DMF to obtain a piogelimide finishedproduct. According to the method, the yield and purity of the product can be effectively improved, the raw material cost is greatly reduced, the production operation is simplified, the production efficiency is improved, and the influence on the environment is greatly reduced.

A PROCESS FOR THE PREPARATION OF 4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]NITROBENZENE AND PIOGLITAZONE

-

Page/Page column 6, (2009/12/05)

A process for the preparation of 4-[2-(5-ethyl-2-pyridyi)ethoxy]nitrobenzene is described, which comprises the step of reacting 2-(5-ethyl-2-pyridyl)ethanol with 1-fluoro-4-nitrobenzene in acetone in the presence of an alkali metal hydroxide. The intermediate 4-[2-(5-ethyl-2-pyridyI)ethoxy]nitrobenzene is used for the preparation of pioglitazone.

An improved process for pioglitazone and its pharmaceutically acceptable salt

Madivada, Lokeswara Rao,Anumala, Raghupathi Reddy,Gilla, Goverdhan,Alla, Sampath,Charagondla, Kavitha,Kagga, Mukkanti,Bhattacharya, Apurba,Bandichhor, Rakeshwar

scheme or table, p. 1190 - 1194 (2010/04/22)

An improved process for pioglitazone (1) is described. The process features high-yielding transformations employing inexpensive reagents and recoverable solvents.

AN IMPROVED PROCESS FOR THE PRODUCTION OF DERIVATIVES OF THIOZOLIDINEDIONES AND THEIR PRECURSORS

-

Page/Page column 21; 22, (2010/10/20)

The invention provides a process for preparing derivatives of thiozolidinediones and their precursors comprising, (a) reacting a compound of general formula I wherein R1, R2 and R3 may be same or different and represent H, alkyl or alkoxy with C varying from 1 to 6, halogens, mono or di-substituted alkyl and aryl amines, and M represents hydrogen (H) or alkali metal selected from Na, K or Li with a compound of formula II, wherein R4 has the same meaning as R1 or R2 or R3 and X is halogen in presence or absence of solvent(s) under effective conditions to produce nitro ethers of general formula III, where in R1 to R4 has the same meaning as given above, provided when M is H and not its alkali metal salt, an alkali metal salt such as hydroxide or carbonate is required to be added while conducting the said reaction, (b) subjecting the said nitro ethers, with or without isolation, to Raney nickel-catalyzed reduction under conditions effective to produce corresponding nitro aniline ethers (c) coupling the said aniline ether with acrylates under Meerwein arylation conditions in presence of hydrobromic acid to produce α bromo substituted carboxylic acid derivatives followed by subjecting to solvent extractive purification (d) cyclising the purified derivative of α bromo substituted carboxylic acid as obtained in step (c) with thiourea to yield 2-imino -4-thiazolidinones then (e) hydrolyzing the said 2-imino-4-thiazolidinones to produce 2, 4-thiazolidinones and converting the same to its hydrochloride salts as white crystalline solids known to exhibit antidiabetic activity, by conventional methods.

Structural characterization of impurities in pioglitazone

Kumar,Reddy,Eswaraiah,Mukkanti,Reddy,Suryanarayana

, p. 836 - 839 (2007/10/03)

In the pioglitazone bulk drug three prominent impurities I-III were detected up to concentrations of 0.1% (ranging from 0.05-0.1%) by reversed phase HPLC. These impurities were isolated from enriched mother liquor samples and characterized as 5-(4-hydroxybenzyl)-1,3-thiazolidine-2,4-dione (I) 5-(4-fluorobenzyl)-1,3-thiazolidine-2,4-dione (II), 2-[2-(4-bromophenoxy) ethyl-5-ethyl pyridine (III) based on their 1H, and 13C NMR, DEPT, Mass and IR spectral data. Structure elucidation and synthesis of these impurities is discussed.

PROCESS FOR THE PREPARATION OF 5-[[4-[2-(5-ETHYL-2-PYRIDINYL)ETHOXY]PHENYL] METHYL]-2,4-THIAZOLIDINEDIONE

-

Page 9-10, (2010/02/09)

A process for the preparation of 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (formula 1) comprising a. reacting diazonium salt of 4-[2-(5-Ethyl-2-pyridyl) ethoxy] amino- benzene, compound of formula 2, with acrylamide, aqueous HX (wherein X is Br or Cl), under meerwein arylation conditions to yield compound of formula 3; b. condensing compound of formula 3 with thiourea to obtain compound of formula 4; and c. converting compound of formula 4 to compound of formula 1.

Ether and amide compounds and preparation of thereof as antidiadetics.

-

, (2008/06/13)

Ether and amide derivatives are disclosed, which are represented by the following formula (I) and its pharmaceutical acceptable salt, and which are useful for the treatment of diabetes. 1(with the provisos that (i) when A is —O—, then n is 2 or 3 (ii) when A is 2then n is 1 or 2. R3 is OH—, CH3SO2NH—, CF3SO2NH—, CH3SO2NHCH2—, CF3SO2NHCH2—, HOOC—, CH3OOC—, 3HOOC—CH2SO2NH—, CF3—CH2SO2NH—, 4R8—NHSO2—, R8—NHSO2—CH2—, HOOC—CH2—O—, HSO3N=CH—, or R9—SO2NHCO—; R4 is H, OH, O-alkyl or O—CH2OCH3; R5 is H, halogen atom, —CH2COOH or OH; R6 and R7 are hydrogen, t-butyl or pyrolidyl; R8 is hydrogen or lower alkyl; R9 is alkyl or thienyl; R10 is lower alkyl) or a pharmaceutically acceptable salt.

Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones

Sohda,Momose,Meguro,Kawamatsu,Sugiyama,Ikeda

, p. 37 - 42 (2007/10/02)

The synthesis of a series of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones is described. These compounds were evaluated for hypoglycemic and hypolipidemic activities in genetically obese and diabetic mice, yellow KK. 2-(2-Pyridyl)alkoxy derivatives were found to have much better hypoglycemic and hypolipidemic activities than 2-(3-pyridyl)- and 2-(4-pyridyl)alkoxy derivatives or even the previously reported compound, ciglitazone. The introduction of a hydroxyl group at the 2-position of the ethoxy chain potentiated the activities. Among the potent compounds, pioglitazone (AD-4833) was selected as a candidate compound.

Herbicidal pyridyl-ethoxy-phenyl urea derivatives

-

, (2008/06/13)

Urea derivatives of the general formula: STR1 wherein R1 stands for a lower alkly group; and R2 stands for a lower alkyl group or a lower alkoxy group, or a salt thereof, are novel and have a strong herbicidal activity against various species of weeds and shows a very low phytotoxicity to crop plants.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 85583-40-0